June 30, 2005

Organon & New Antipsychotic

Organon achieves milestone in asenapine development

In the past, we've reported on the development of Asenapine: a drug which is supposed to treat psychotic and mood disorders. Recently, it seems that Organon ( Akzo Nobel ), the company responsible for asenapine "has achieved a development milestone for (the drug)..." This "milestone has resulted in a retroactive change in the division of full Phase III development costs, with the co-collaborator, Pfizer , increasing its (asenapine's) share; the agreed future revenue sharing will remain in place. The milestone, which relates to satisfactory results in the companies' clinical trial programme and the achievement of it, of which no further specifics were disclosed, reconfirms the commitment of both companies to fully explore the clinical potential of asenapine."

Though early clinical trials demonstrate that Asenapine will "restore balance to a patient's life through superior releif of negative symptoms," it's important to wait for further results before drawing any solid conclusions. Regardless, Asenapine has been described as having "a unique neuropharmacological receptor signature that distinguishes it from current antipsychotics, antidepressants and mood stabilisers." Thus, it sounds promising.

Full Story:

More Information:


I am a participant in Pfizer's study on Aesenapine. I am in Phase I trial now, South Florida.

Posted by: Jeanne at January 18, 2006 05:33 AM

Dear Sir / Madam,
I read about asenapine. What is its market name? I want to find and buy it.

Posted by: Plamen at July 26, 2006 12:18 PM

Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required